Search

Your search keyword '"Poggio, F"' showing total 377 results

Search Constraints

Start Over You searched for: Author "Poggio, F" Remove constraint Author: "Poggio, F"
377 results on '"Poggio, F"'

Search Results

1. Efficacy of adjuvant chemotherapy schedules for breast cancer according to body mass index: results from the phase III GIM2 trial

2. Eribulin in combination with bevacizumab as second-line treatment for HER2-negative metastatic breast cancer progressing after first-line therapy with paclitaxel and bevacizumab: a multicenter, phase II, single arm trial (GIM11-BERGI)

3. VISTA: A Promising Target for Cancer Immunotherapy?

4. 35P SNPs of aromatase gene (CYP19A1) and outcomes of patients with estrogen receptor-positive (ER+) early breast cancer (eBC) treated with aromatase inhibitors (AIs): A multicenter, prospective study

5. 108P Safety results of post-neoadjuvant T-DM1 in the Italian compassionate use program (GIM26-TRASTHER study)

7. 134O Dose-dense adjuvant chemotherapy in early-stage breast cancer patients: End-of-study results from a randomised, phase III trial of the Gruppo Italiano Mammella (GIM)

8. P-463 Anti-Müllerian hormone levels in breast cancer patients receiving chemotherapy with or without concurrent luteinizing hormone-releasing hormone agonist: results from the PROMISE phase III trial

9. 69P Impact of statin use on survival outcomes of patients with HER2-positive early breast cancer in the APHINITY trial

10. Bulk Explosive Detection by Neutron Interrogation: Results from the Explodet Collaboration.

15. Corrigendum to ‘Eribulin in combination with bevacizumab as second-line treatment for HER2-negative metastatic breast cancer progressing after first-line therapy with paclitaxel and bevacizumab: a multicenter, phase II, single arm trial (GIM11-BERGI)’: [ESMO Open Volume 6, Issue 2, April 2021, 100054]

16. 307P Overall survival in metastatic breast cancer patients according to different follow up strategies for early breast cancer

17. 118O Extended therapy with letrozole as adjuvant treatment of postmenopausal patients with early-stage breast cancer: A randomised, phase III trial of the Gruppo Italiano Mammella

19. Final results of the tests on the resistive plate chambers for the ALICE muon arm

21. Production of pions, kaons and protons in pp collisions at $\sqrt{s}= 900~\mathrm{GeV}$ with ALICE at the LHC

22. Zero degree Cherenkov calorimeters for the ALICE experiment

23. Charged-particle multiplicity measurement in proton–proton collisions at $\sqrt{s}=7$ TeV with ALICE at LHC

24. Charged-particle multiplicity measurement in proton–proton collisions at $\sqrt{s}=0.9$ and 2.36 TeV with ALICE at LHC

25. First proton–proton collisions at the LHC as observed with the ALICE detector: measurement of the charged-particle pseudorapidity density at $\sqrt{s}=900$  GeV

28. Performance of the zero degree calorimeters for the ALICE experiment

29. The zero degree calorimeters for the ALICE experiment

30. Front-end electronics for the RPCs of the ALICE dimuon trigger

31. Performances of a prototype for the ALICE muon trigger at LHC

32. Beam and ageing tests with a highly–saturated avalanche gas mixture for the ALICE p–p data taking

34. Design and Performance of the ALICE Muon Trigger System

35. Overview on production and first results of the tests on the RPCs for the ALICE dimuon trigger

36. The Neutron Zero Degree Calorimeter for the ALICE experiment

37. 226P Impact of BMI on outcome and cardiac safety in HER2-positive breast cancer patients treated with adjuvant trastuzumab: Results of a monocentric observational study

38. 1740P Assessing the impact of COVID-19 outbreak on the attitudes and practice of Italian oncologists towards breast cancer care and related research activities

39. 1700P Perception and attitudes of Italian physicians towards the management of checkpoint inhibitors in oncology during COVID-19 outbreak: Results from a national survey

40. 95TiP Gruppo Italiano Mammella (GIM) 10 – CONSENT: A phase III randomized study comparing concurrent versus sequential administration of adjuvant chemotherapy (CT) and aromatase inhibitors (AIs) in post-menopausal patients (pts) with hormone receptor-positive (HR+) early breast cancer (EBC)

41. 148P Surgery (Sx) of the primary tumour in de novo metastatic breast cancer (BC) patients (pts) is associated with increased survival: A nationwide population-based study by the Belgian Cancer Registry (BCR) and the Belgian Society of Medical Oncology (BSMO)

42. Efficacy of dose-dense (DD) adjuvant chemotherapy (CT) in hormone receptor positive/HER2-negative early breast cancer (BC) patients (pts) according to immunohistochemically (IHC) defined luminal subtypes: An exploratory analysis of the GIM2 trial

45. Ageing tests on the low-resistivity RPC for the ALICE dimuon arm

47. The role of dose-dense (DD) adjuvant chemotherapy (CT) in HER2-positive (HER2+) early breast cancer (BC) patients (pts) before and after the introduction of trastuzumab (T): Exploratory analysis of the GIM2 trial

48. Effectiveness of trastuzumab emtansine (TDM1) in patients with HER2-positive advanced breast cancer (ABC) progressing after taxane plus pertuzumab plus trastuzumab

50. Physicians’ knowledge, attitudes and practice towards fertility and pregnancy-related issues in BRCA-mutated breast cancer (BC) patients (pts): Results from the BCY3/BCC 2017 survey

Catalog

Books, media, physical & digital resources